IBRX vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELAN
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.
ImmunityBio vs.
Qiagen (NYSE:QGEN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
In the previous week, Qiagen had 5 more articles in the media than ImmunityBio. MarketBeat recorded 13 mentions for Qiagen and 8 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.13 beat Qiagen's score of -0.37 indicating that ImmunityBio is being referred to more favorably in the news media.
Qiagen presently has a consensus target price of $47.71, indicating a potential upside of 22.80%. ImmunityBio has a consensus target price of $13.58, indicating a potential upside of 286.44%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Qiagen.
Qiagen has a net margin of 4.23% compared to ImmunityBio's net margin of -8,016.83%. Qiagen's return on equity of 13.92% beat ImmunityBio's return on equity.
70.0% of Qiagen shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 83.4% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Qiagen has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Qiagen has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Qiagen received 238 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 60.29% of users gave Qiagen an outperform vote while only 34.38% of users gave ImmunityBio an outperform vote.
Summary
Qiagen beats ImmunityBio on 12 of the 19 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
This page (NASDAQ:IBRX) was last updated on 2/21/2025 by MarketBeat.com Staff
